Overview

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants

Status:
Not yet recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 that are not hospitalized at the time of enrollment.
Phase:
Phase 2
Details
Lead Sponsor:
Clene Nanomedicine
Collaborators:
Azidus Brazil
ICL Pharma